TY - JOUR
T1 - Integrating patient priorities with science by community engagement in the kidney precision medicine project
AU - Kidney Precision Medicine Project
AU - Tuttle, Katherine R.
AU - Knight, Richard
AU - Appelbaum, Paul S.
AU - Arora, Tanima
AU - Bansal, Shweta
AU - Bebiak, Jack
AU - Brown, Keith
AU - Campbell, Catherine
AU - Cooperman, Leslie
AU - Corona-Villalobos, Celia P.
AU - Dighe, Ashveena
AU - de Boer, Ian H.
AU - Hall, Daniel E.
AU - Jefferson, Nichole
AU - Jolly, Stacey
AU - Kermani, Asra
AU - Lee, Simon C.
AU - Mehl, Karla
AU - Murugan, Raghavan
AU - Roberts, Glenda V.
AU - Rosas, Sylvia E.
AU - Himmelfarb, Jonathan
AU - Miller, R. Tyler
N1 - Funding Information:
S. Bansal reports receiving author royalties from UpToDate, other from Home Therapy Institute, and other from Osprey Medical, outside the submitted work. As a KPMP patient partner, K. Brown receives reimbursement for his travel to in-person meetings. There are typically two in-person meetings per year. He also receives a consulting fee of $200 per meeting day for these in-person meetings. As a KPMP patient partner, C. Campbell receives reimbursement for her travel to in-person meetings. There are typically two in-person meetings per year. She also receives a consulting fee of $200 per meeting day for these in-person meetings. I. de Boer reports receiving grants from the American Diabetes Association, Juvenile Diabetes Research Foundation, the National Heart, Lung, and Blood Institute, and NIDDK; consulting fees from Boehringer Ingelheim, Cyclerion Therapeutics, George Clinical, Goldfinch Bio, and Ironwood; and research equipment and supplies from Abbott and Medtronic, outside the submitted work. K. Mehl reports receiving grants from Columbia University during the conduct of the study. R. Murugan reports receiving grants and personal fees from LaJolla, Inc., grants from Bioporto, and grants from NIDDK during the conduct of the study. He also reports receiving personal fees from AM Pharma and Beckman Coulter, outside the submitted work. G. Roberts reports receiving grants from the Center for Dialysis Innovation; travel and living expenses from the American Society of Nephrology, APOL1 CAB, APOL1 Delphi, the International Society of Nephrology, and the National Kidney Foundation; and honoraria from the APOL1 Long-term Kidney Transplantation Outcomes Network (NIDDK) and KPMP, outside the submitted work. S. Rosas attended one scientific advisory board each for Bayer and Reata in 2019, for which she was compensated. K. Tuttle reports receiving personal fees as a consultant for diabetes and CKD from Astra Zeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Gilead, and Novo Nordisk and grants and personal fees from Goldfinch Bio, outside the submitted work. All remaining authors have nothing to disclose.
Funding Information:
The KPMP is funded by National Institute of Diabetes and Digestive and Kidney Diseases grants U2C DK114886, UH3DK114861, UH3DK114866, UH3DK114870, UH3DK114907, UH3DK114908, UH3DK114915, UH3DK114920, UH3DK114923, UH3DK114926, UH3DK114933, and UH3DK114937.
Publisher Copyright:
© 2021 by the American Society of Nephrology.
PY - 2021/4/7
Y1 - 2021/4/7
N2 - The Kidney Precision Medicine Project (KPMP) is a multisite study designed to improve understanding of CKD attributed to diabetes or hypertension and AKI by performing protocol-driven kidney biopsies. Study participants and their kidney tissue samples undergo state-of-the-art deep phenotyping using advanced molecular, imaging, and data analytical methods. Few patients participate in research design or concepts for discovery science. A major goal ofthe KPMPis to include patients as equal partners toinform the research for clinically relevant benefit.The purpose of this report is to describe patient and community engagement and the value they bring to the KPMP. Patients with CKD and AKI and clinicians from the study sites are members of the Community Engagement Committee, with representation on other KPMP committees. They participate in KPMP deliberations to address scientific, clinical, logistic, analytic, ethical, and community engagement issues. The Community Engagement Committee guides KPMP research priorities from perspectives of patients and clinicians. Patients led development of essential study components, including the informed consent process, no-fault harm insurance coverage, the ethics statement, return of results plan, a “Patient Primer” for scientists and the public, and Community Advisory Boards. As members across other KPMP committees, the Community Engagement Committee assures that the science is developed and conducted in a manner relevant to study participants and the clinical community. Patients have guided the KPMP to produce research aligned with their priorities. The Community Engagement Committee partnership has set new benchmarks for patient leadership in precision medicine research.
AB - The Kidney Precision Medicine Project (KPMP) is a multisite study designed to improve understanding of CKD attributed to diabetes or hypertension and AKI by performing protocol-driven kidney biopsies. Study participants and their kidney tissue samples undergo state-of-the-art deep phenotyping using advanced molecular, imaging, and data analytical methods. Few patients participate in research design or concepts for discovery science. A major goal ofthe KPMPis to include patients as equal partners toinform the research for clinically relevant benefit.The purpose of this report is to describe patient and community engagement and the value they bring to the KPMP. Patients with CKD and AKI and clinicians from the study sites are members of the Community Engagement Committee, with representation on other KPMP committees. They participate in KPMP deliberations to address scientific, clinical, logistic, analytic, ethical, and community engagement issues. The Community Engagement Committee guides KPMP research priorities from perspectives of patients and clinicians. Patients led development of essential study components, including the informed consent process, no-fault harm insurance coverage, the ethics statement, return of results plan, a “Patient Primer” for scientists and the public, and Community Advisory Boards. As members across other KPMP committees, the Community Engagement Committee assures that the science is developed and conducted in a manner relevant to study participants and the clinical community. Patients have guided the KPMP to produce research aligned with their priorities. The Community Engagement Committee partnership has set new benchmarks for patient leadership in precision medicine research.
UR - http://www.scopus.com/inward/record.url?scp=85101176844&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101176844&partnerID=8YFLogxK
U2 - 10.2215/CJN.10270620
DO - 10.2215/CJN.10270620
M3 - Article
C2 - 33257411
AN - SCOPUS:85101176844
SN - 1555-9041
VL - 16
SP - 660
EP - 668
JO - Clinical Journal of the American Society of Nephrology
JF - Clinical Journal of the American Society of Nephrology
IS - 4
ER -